Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof. Carrying out the method unexpectedly reduces the need for subsequent invasive surgical intervention.

Abstract: The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.

Abstract: Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

Abstract: The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.

Abstract: Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

Abstract: Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient. The methods are particularly effective in improving urinary peak flow (Qmax), and in improving nocturia.

Abstract: The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.

Abstract: The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.

Abstract: The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.

Abstract: Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.

Abstract: The embodiments include methods of improving the symptoms of mammals having LUTS, using compositions containing Fexapotide Triflutate and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering Fexapotide Triflutate intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or with a carrier to a mammal in need thereof.

Abstract: Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient. The methods are particularly effective in improving urinary peak flow (Qmax), and in improving nocturia.

Abstract: Disclosed are methods of improving the symptoms of mammals suffering from BPH using compositions containing one or more antibiotics. The method includes, but is not limited to, administering at least one antibiotic in one or more courses of treatment by one or more administration routes selected from intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, and transdermally, either alone or with a carrier to a mammal in need thereof.

Abstract: Disclosed are methods of selective glandular pharmaco-ablation using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The methods of selectively destroying prostate gland overgrowth substantially or completely preserve key nerve, stromal, vascular, connective tissue, urethral musculature, and structural elements in intimate structural proximity to the foci of ablation.

Abstract: The embodiments include methods of ameliorating or preventing the worsening or progression and/or ameliorating or preventing the worsening or lack of improvement of symptoms of BPH in mammals, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.

Abstract: Disclosed are methods of improving the symptoms of mammals suffering from BPH using compositions containing one or more antibiotics. The method includes, but is not limited to, administering at least one antibiotic in one or more courses of treatment by one or more administration routes selected from intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, and transdermally, either alone or with a carrier to a mammal in need thereof.

Abstract: The embodiments include methods of improving sexual function in a male with benign prostatic hyperplasia (BPH), using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a male in need thereof.

Abstract: The embodiments include methods of preventing or reducing the progression of prostate cancer in mammals susceptible to developing prostate cancer, and to methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.

Abstract: Methods of preventing or reducing the incidence of acute urinary retention in mammals susceptible to developing acute urinary retention, and methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier, are described. The methods include, but are not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.

Abstract: The embodiments include methods of improving sexual function in a male with benign prostatic hyperplasia (BPH), using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a male in need thereof.